 GAITHERSBURG, Md., Sept. 29, 2021 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader KOL call on its 12-week Phase 1 clinical trial of pemvidutide proposed INN, formerly known as ALT-801 in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST. 